# A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）

> **NCT07191431** · NA · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Lymphoma Cns

## Interventions

- **DRUG:** Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide

## Key facts

- **NCT ID:** NCT07191431
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2027-09-02
- **Final completion:** 2029-09-02
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191431, "A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07191431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*